Hepatitis B Virus (HBV)

Atorvastatin calcium: SAFETY(4)

Atorvastatin calcium: SAFETY(4)

Analysis of atorvastatin-treated patients receiving concomitant antihypertensive therapy, hypoglycemic agents or estrogen replacement therapy showed no clinically significant adverse interactions. The following drug interactions are reported in the product monograph for ator-vastatin. Coadministration of atorvastatin with colestipol resulted in lower plasma concentrations of atorvastatin; however, LDL-C reduction was greater with the combination than with either agent alone.

Coadministration with an aluminum- and magnesium-based antacid decreased plasma concentrations of atorvastatin; however, LDL-C reduction was not altered. Plasma concentrations of atorvastatin increased upon concurrent administration with erythromycin, and coadministration of atorvastatin and digoxin increased plasma digoxin concentrations. Such patients should, therefore, be monitored appropriately. Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin therapy . Finally, although two studies reported increased fibrinogen levels following treatment with atorvastatin , several other studies, including an analysis of data in over 900 patients, have shown no clinically meaningful effect of ator-vastatin on fibrinogen.

Category: Calcium

Tags: Atorvastatin, Coronary artery disease, Dyslipidemia, HMG-CoA reductase inhibitors, Hypercholesterolemia, Statins

Leave a Reply

Your email address will not be published. Required fields are marked *